Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Robin M.J.M. van Geel"'
Autor:
Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100656- (2024)
Introduction: Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic
Externí odkaz:
https://doaj.org/article/b8cb56c1a21d4838abe7a2a929f0a009
Autor:
Leila S. Otten, Berber Piet, Michel M. van den Heuvel, Catia Marzolini, Robin M.J.M. van Geel, Judith L. Gulikers, David M. Burger, Jenneke Leentjens, Rob ter Heine
Publikováno v:
European Respiratory Review, Vol 31, Iss 164 (2022)
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients is increased and often requires treatment or prophylaxis with direct oral anticoagulants (DOACs). Small-molecule inhibitors (SMIs) to treat NSCLC may cause relevan
Externí odkaz:
https://doaj.org/article/021ff43369ae431abd9f0b019aca1b8f
Autor:
Jan H.M. Schellens, Tim Demuth, Kati Maharry, Eugene Tan, Savina Jaeger, Arkendu Chatterjee, Emin Avsar, Zev A. Wainberg, Heinz-Josef Lenz, Rona Yaeger, Sunil Sharma, Ferry A.L.M. Eskens, Jason E. Faris, Martijn P. Lolkema, Yasuhide Yamada, Jean-Pierre Delord, Takayuki Yoshino, Martin Schuler, Anna Spreafico, Johanna C. Bendell, Elena Elez, Josep Tabernero, Robin M.J.M. van Geel
Table S1. Pharmacokinetic parameters of encorafenib and alpelisib in patients at steady state (cycle 2 day 1). Table S2. Criteria for defining dose-limited toxicities. Supplementary Figure 1. Radiological images of response for a patient treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1341dd8cec12a541df23cf9cbed4ad9b
https://doi.org/10.1158/2159-8290.22532039
https://doi.org/10.1158/2159-8290.22532039
Autor:
Federica Di Nicolantonio, Ryan B. Corcoran, Salvatore Siena, Alberto Bardelli, Andrea Sartore-Bianchi, Jeffrey A. Engelman, Josep Tabernero, Jan H.M. Schellens, René Bernards, Margherita Gallicchio, Julieta Grasselli, Giulia Siravegna, Mauro Truini, Giorgio Corti, Michael Linnebacher, Carlotta Cancelliere, Michela Buscarino, Jason T. Godfrey, Valentina Boscaro, Giovanni Crisafulli, Alice Bartolini, Robin M.J.M. van Geel, Elena Elez, Giulia Marzolla, Genny Filiciotto, Andrea Cassingena, Sabrina Arena, Emanuele Valtorta, Ludovic Barault, Erin M. Sennott, Daniele Oddo
The file lists Supplementary Materials and Methods and relative References.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13b498f8adc90bf218a6ea043154f15e
https://doi.org/10.1158/0008-5472.22413579
https://doi.org/10.1158/0008-5472.22413579
Autor:
Federica Di Nicolantonio, Ryan B. Corcoran, Salvatore Siena, Alberto Bardelli, Andrea Sartore-Bianchi, Jeffrey A. Engelman, Josep Tabernero, Jan H.M. Schellens, René Bernards, Margherita Gallicchio, Julieta Grasselli, Giulia Siravegna, Mauro Truini, Giorgio Corti, Michael Linnebacher, Carlotta Cancelliere, Michela Buscarino, Jason T. Godfrey, Valentina Boscaro, Giovanni Crisafulli, Alice Bartolini, Robin M.J.M. van Geel, Elena Elez, Giulia Marzolla, Genny Filiciotto, Andrea Cassingena, Sabrina Arena, Emanuele Valtorta, Ludovic Barault, Erin M. Sennott, Daniele Oddo
Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF-mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd302bf0210c3bfc933df8f749f88ac8
https://doi.org/10.1158/0008-5472.c.6508761.v1
https://doi.org/10.1158/0008-5472.c.6508761.v1
Autor:
Federica Di Nicolantonio, Ryan B. Corcoran, Salvatore Siena, Alberto Bardelli, Andrea Sartore-Bianchi, Jeffrey A. Engelman, Josep Tabernero, Jan H.M. Schellens, René Bernards, Margherita Gallicchio, Julieta Grasselli, Giulia Siravegna, Mauro Truini, Giorgio Corti, Michael Linnebacher, Carlotta Cancelliere, Michela Buscarino, Jason T. Godfrey, Valentina Boscaro, Giovanni Crisafulli, Alice Bartolini, Robin M.J.M. van Geel, Elena Elez, Giulia Marzolla, Genny Filiciotto, Andrea Cassingena, Sabrina Arena, Emanuele Valtorta, Ludovic Barault, Erin M. Sennott, Daniele Oddo
Supplementary Tables S1-S3 - List of drug concentrations to generate resistant cell lines (S1); Drug concentrations applied in the screening depicted in Figure 6 (S2); Primers for gene amplification and sequencing (S3). Supplementary Figure S1. Syner
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::830ffd5c23cf95e6083c2e506f487ecb
https://doi.org/10.1158/0008-5472.22413582
https://doi.org/10.1158/0008-5472.22413582
Autor:
Federica Di Nicolantonio, Ryan B. Corcoran, Salvatore Siena, Alberto Bardelli, Andrea Sartore-Bianchi, Jeffrey A. Engelman, Josep Tabernero, Jan H.M. Schellens, René Bernards, Margherita Gallicchio, Julieta Grasselli, Giulia Siravegna, Mauro Truini, Giorgio Corti, Michael Linnebacher, Carlotta Cancelliere, Michela Buscarino, Jason T. Godfrey, Valentina Boscaro, Giovanni Crisafulli, Alice Bartolini, Robin M.J.M. van Geel, Elena Elez, Giulia Marzolla, Genny Filiciotto, Andrea Cassingena, Sabrina Arena, Emanuele Valtorta, Ludovic Barault, Erin M. Sennott, Daniele Oddo
Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76ae184372f1020068c41c3a360c8e56
https://doi.org/10.1158/0008-5472.22413585
https://doi.org/10.1158/0008-5472.22413585
Autor:
Sunil Sharma, Emin Avsar, Kati Maharry, Jan H.M. Schellens, Anna Spreafico, Rona Yaeger, Martin Schuler, Jason E. Faris, Takayuki Yoshino, Arkendu Chatterjee, Savina Jaeger, Ferry A.L.M. Eskens, Johanna C. Bendell, Tim Demuth, Josep Tabernero, Martijn P. Lolkema, Zev A. Wainberg, Yasuhide Yamada, Jean Pierre Delord, Robin M.J.M. van Geel, Eugene Tan, Elena Elez, Heinz-Josef Lenz
Publikováno v:
Cancer Discovery, 7(6), 610-619. American Association for Cancer Research Inc.
Cancer discovery, vol 7, iss 6
Cancer Discovery, 7(6), 610. American Association for Cancer Research Inc.
Cancer discovery, vol 7, iss 6
Cancer Discovery, 7(6), 610. American Association for Cancer Research Inc.
Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and suppressed tumor growth in BRAFV600E colorectal cancer models. Patients with refractory BRAFV600-mutant metastatic CRC (mCRC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a74efca771fba8318569827a37a712f
https://hdl.handle.net/1765/108310
https://hdl.handle.net/1765/108310
Autor:
Andrea Sartore-Bianchi, Margherita Gallicchio, Erin M. Sennott, Alice Bartolini, Federica Di Nicolantonio, Julieta Grasselli, Valentina Boscaro, Alberto Bardelli, Jan H.M. Schellens, Giovanni Crisafulli, Salvatore Siena, Jason T. Godfrey, Andrea Cassingena, Jeffrey A. Engelman, Genny Filiciotto, Giorgio Corti, Giulia Siravegna, Mauro Truini, Josep Tabernero, Giulia Marzolla, Michael Linnebacher, Carlotta Cancelliere, Sabrina Arena, René Bernards, Emanuele Valtorta, Ludovic Barault, Daniele Oddo, Michela Buscarino, Ryan B. Corcoran, Elena Elez, Robin M.J.M. van Geel
Publikováno v:
Cancer Research
Cancer Research, 76(15), 4504-4515. American Association for Cancer Research Inc.
Cancer Research, 76(15), 4504-4515. American Association for Cancer Research Inc.
Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF-mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0b75892ae1f547d111434229a042c4a
https://cris.maastrichtuniversity.nl/en/publications/d6475322-dc21-4472-a221-427cede7b2e7
https://cris.maastrichtuniversity.nl/en/publications/d6475322-dc21-4472-a221-427cede7b2e7
Publikováno v:
Current Colorectal Cancer Reports
Current Colorectal Cancer Reports, 11(6), 335. Springer Science + Business Media
Current Colorectal Cancer Reports, 11(6), 335. Springer Science + Business Media
Colorectal cancer has been characterized as a genetically heterogeneous disease, with a large diversity in molecular pathogenesis resulting in differential responses to therapy. However, the currently available validated biomarkers KRAS, BRAF, and mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82e851f3ce9847c2340908738c71d693
http://europepmc.org/articles/PMC4653238
http://europepmc.org/articles/PMC4653238